0001104659-21-141746.txt : 20211119
0001104659-21-141746.hdr.sgml : 20211119
20211119132805
ACCESSION NUMBER: 0001104659-21-141746
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20211117
FILED AS OF DATE: 20211119
DATE AS OF CHANGE: 20211119
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Kamarck Michael E.
CENTRAL INDEX KEY: 0001450730
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-36596
FILM NUMBER: 211427682
MAIL ADDRESS:
STREET 1: C/O UNILIFE CORPORATION
STREET 2: 250 CROSS FARM LANE
CITY: YORK
STATE: PA
ZIP: 17406
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Trillium Therapeutics Inc.
CENTRAL INDEX KEY: 0001616212
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 000000000
STATE OF INCORPORATION: A1
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 2488 DUNWIN DRIVE
CITY: MISSISSAUGA
STATE: A6
ZIP: L5L 1J9
BUSINESS PHONE: (416) 595-0627
MAIL ADDRESS:
STREET 1: 2488 DUNWIN DRIVE
CITY: MISSISSAUGA
STATE: A6
ZIP: L5L 1J9
4
1
tm2133436-6_4seq1.xml
OWNERSHIP DOCUMENT
X0306
4
2021-11-17
1
0001616212
Trillium Therapeutics Inc.
TRIL
0001450730
Kamarck Michael E.
C/O TRILLIUM THERAPEUTICS INC.
2488 DUNWIN DRIVE
MISSISSAUGA
A6
L5L 1J9
ONTARIO, CANADA
1
0
0
0
Stock Option (Right to Buy)
14.77
2021-11-17
4
D
0
67000
0
D
2030-09-17
Common Shares
67000
0
D
On November 17, 2021 (the "Closing Date"), PF Argentum Acquisition ULC, an indirect wholly owned subsidiary of Pfizer, Inc. (the "Purchaser") acquired all of the outstanding common shares of Trillium Therapeutics Inc. (the "Issuer") under a plan of arrangement pursuant to the Canada Business Corporations Act (British Columbia) (the "Plan of Arrangement"), whereby Issuer became a wholly owned subsidiary of the Purchaser. At the Effective Time (the "Effective Time") of the Plan of Arrangement, all common shares and equity awards of the Issuer that were issued and outstanding immediately prior to the Effective Time were converted into the right to receive $18.50 per share in cash.
/s/ James Parsons, Attorney-in-Fact
2021-11-19